BR0307477A - Compostos quìmicos - Google Patents

Compostos quìmicos

Info

Publication number
BR0307477A
BR0307477A BR0307477-3A BR0307477A BR0307477A BR 0307477 A BR0307477 A BR 0307477A BR 0307477 A BR0307477 A BR 0307477A BR 0307477 A BR0307477 A BR 0307477A
Authority
BR
Brazil
Prior art keywords
compounds
chemical compounds
bond
optionally substituted
manufacturing
Prior art date
Application number
BR0307477-3A
Other languages
English (en)
Inventor
Lilian Alcaraz
Mark Furber
Mark Purdie
Brian Springthorpe
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0200465A external-priority patent/SE0200465D0/xx
Priority claimed from SE0202673A external-priority patent/SE0202673D0/xx
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BR0307477A publication Critical patent/BR0307477A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)

Abstract

"COMPOSTOS QUìMICOS". A presente invenção se refere a compostos de fórmula (I): em que: X é CH~ 2~, O, S (O)~ 2~ ou NR^ 10^ ; Y é uma ligação, CH~ 2~, NR^ 35^, CH~ 2~NH, CH~ 2~NHC (O) , CH(OH), CH(NHCOR^ 33^), CH (NHSO~ 2~R^ 34^), CH~ 2~O ou CH~ 2~S; Z é C(O) ou quando Y for uma ligação, Z pode também ser S(O)~ 2~; R^ 1^ é arila opcionalmente substituído, heterociclila opcionalmente substituído OU C~ 4-6~ cicloalquila fundido a um anel de benzeno; e R^ 2^, R^ 3^ , R^ 4^, R^ 5^, R^ 6^ , R^ 7^ e R^ 8^, R^ 9^, R~ 10~, R^ 32^, R^ 33^, R^ 34~ e R^ 35^ são como aqui definido. Esses compostos são moduladores da atividade de quimocina (especialmente da CCR3), para uso, por exemplo, no tratamento de asma. A invenção também proporciona um processo para fabricação do composto de 4-(3,4-diclorofenóxi)piperidina, que é de utilidade como intermediário para fabricação de certos compostos da invenção.
BR0307477-3A 2002-02-18 2003-02-17 Compostos quìmicos BR0307477A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0200465A SE0200465D0 (sv) 2002-02-18 2002-02-18 Chemical compounds
SE0202673A SE0202673D0 (sv) 2002-09-09 2002-09-09 Chemical compounds
PCT/SE2003/000258 WO2003068743A1 (en) 2002-02-18 2003-02-17 Chemical compounds

Publications (1)

Publication Number Publication Date
BR0307477A true BR0307477A (pt) 2004-11-09

Family

ID=27736686

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0307477-3A BR0307477A (pt) 2002-02-18 2003-02-17 Compostos quìmicos

Country Status (22)

Country Link
US (1) US7709500B2 (pt)
EP (1) EP1478624B1 (pt)
JP (1) JP4435571B2 (pt)
KR (1) KR20040084920A (pt)
CN (1) CN100352807C (pt)
AR (1) AR038566A1 (pt)
AT (1) ATE480518T1 (pt)
AU (1) AU2003206554B2 (pt)
BR (1) BR0307477A (pt)
CA (1) CA2472822A1 (pt)
CO (1) CO5611135A2 (pt)
DE (1) DE60334074D1 (pt)
IL (1) IL195011A0 (pt)
IS (1) IS7381A (pt)
MX (1) MXPA04007906A (pt)
NO (1) NO20043899L (pt)
NZ (1) NZ534296A (pt)
PL (1) PL372538A1 (pt)
RU (2) RU2330019C2 (pt)
SG (1) SG149695A1 (pt)
TW (1) TW200303304A (pt)
WO (1) WO2003068743A1 (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR028948A1 (es) 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
TW200303304A (en) 2002-02-18 2003-09-01 Astrazeneca Ab Chemical compounds
WO2004037814A1 (en) * 2002-10-25 2004-05-06 Vertex Pharmaceuticals Incorporated Indazolinone compositions useful as kinase inhibitors
SE0400208D0 (sv) * 2004-02-02 2004-02-02 Astrazeneca Ab Chemical compounds
US7521560B2 (en) 2004-06-29 2009-04-21 Rigel Pharmaceuticals, Inc. 2-substituted quinoline compounds and their uses
JP3964417B2 (ja) 2004-09-27 2007-08-22 国立大学法人金沢大学 インドール誘導体を有効成分とするα２受容体遮断剤及び血管拡張剤
SE0403003D0 (sv) * 2004-12-09 2004-12-09 Astrazeneca Ab Chemical compound 1
US20060167044A1 (en) * 2004-12-20 2006-07-27 Arnaiz Damian O Piperidine derivatives and their use as anti-inflammatory agents
WO2007014054A2 (en) * 2005-07-22 2007-02-01 Glaxo Group Limted Benzenesulfonamide inhibitor of ccr2 chemokine receptor
TW200734305A (en) * 2005-08-02 2007-09-16 Astrazeneca Ab New salt III
TW200738635A (en) * 2005-08-02 2007-10-16 Astrazeneca Ab New salt
TW200738634A (en) * 2005-08-02 2007-10-16 Astrazeneca Ab New salt
BRPI0709596A2 (pt) * 2006-03-16 2011-07-19 Renovis Inc compostos bicicloeteroarila como moduladores de p2x7 e seus usos
TW200812582A (en) * 2006-04-06 2008-03-16 Astrazeneca Ab Medicaments
JP2007297305A (ja) * 2006-04-28 2007-11-15 Daiso Co Ltd Ｎ−（２，３−エポキシ−２−メチルプロピル）フタルイミドの製造法
DE102006060598A1 (de) * 2006-12-21 2008-06-26 Merck Patent Gmbh Tetrahydrobenzoisoxazole
CN101743242A (zh) * 2007-06-29 2010-06-16 苏尼西斯制药有限公司 用作raf激酶抑制剂的杂环化合物
JP5588167B2 (ja) * 2009-12-28 2014-09-10 ライオン株式会社 育毛養毛剤、毛周期変換剤および育毛養毛組成物
JP5864546B2 (ja) 2010-05-07 2016-02-17 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ インダゾール
CA2838777C (en) * 2011-06-10 2019-04-30 Chiesi Farmaceutici S.P.A. Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
CN104603130B (zh) * 2012-04-13 2018-04-27 Epizyme股份有限公司 人类组蛋白甲基转移酶ezh2抑制剂的盐形式
JP2016518401A (ja) 2013-05-08 2016-06-23 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ 抗菌活性を有するフタリド誘導体
MA41140A (fr) * 2014-12-12 2017-10-17 Cancer Research Tech Ltd Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg
MA41179A (fr) 2014-12-19 2017-10-24 Cancer Research Tech Ltd Composés inhibiteurs de parg
CN107674013B (zh) * 2016-08-02 2022-05-24 上海迪诺医药科技有限公司 多环化合物、其制备方法、药物组合物及应用
BR112019025355A2 (pt) * 2017-05-30 2020-06-23 Millennium Pharmaceuticals, Inc. Método para a produção de composto oticamente ativo
KR102650222B1 (ko) 2023-02-14 2024-03-21 (주)오송 살균제용 조성물 및 이를 이용한 제품

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL118768A (en) * 1995-07-12 2000-10-31 Akzo Nobel Nv Diphenylmethane piperidine derivatives pharmaceutical compositions containing them and a method for their preparation
JPH0977742A (ja) 1995-09-12 1997-03-25 Kyorin Pharmaceut Co Ltd 新規なベンズアミド誘導体
ZA9610738B (en) 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
ATE248818T1 (de) 1996-10-28 2003-09-15 Schering Corp Substituierte arylalkylamine als neurokinin- antagonisten
US6124319A (en) * 1997-01-21 2000-09-26 Merck & Co., Inc. 3,3-disubstituted piperidines as modulators of chemokine receptor activity
JP2002510327A (ja) 1997-07-25 2002-04-02 メルク エンド カンパニー インコーポレーテッド 環状アミンケモカイン受容体活性調節剤
IL125658A0 (en) * 1997-08-18 1999-04-11 Hoffmann La Roche Ccr-3 receptor antagonists
US6166037A (en) * 1997-08-28 2000-12-26 Merck & Co., Inc. Pyrrolidine and piperidine modulators of chemokine receptor activity
US6140349A (en) * 1998-02-02 2000-10-31 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
GB9919776D0 (en) * 1998-08-31 1999-10-27 Zeneca Ltd Compoujnds
PT1131291E (pt) * 1998-11-17 2005-01-31 Hoffmann La Roche Antagonistas iii do receptor 4-aroil-piperidin-ccr-3
JP3421323B2 (ja) 1998-11-20 2003-06-30 エフ．ホフマン−ラ ロシュ アーゲー ピペリジンｃｃｒ−３受容体拮抗薬
ATE271032T1 (de) 1998-11-25 2004-07-15 Gene Therapy Systems Inc Amphiphile polyamin verbindungen
US6369112B1 (en) * 1998-12-15 2002-04-09 Bausch & Lomb Incorporated Treatment of contact lenses with aqueous solution comprising a biguanide disinfectant stabilized by tyloxapol
AU2482100A (en) 1998-12-18 2000-07-03 Du Pont Pharmaceuticals Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
US6331541B1 (en) * 1998-12-18 2001-12-18 Soo S. Ko N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
CA2347909A1 (en) 1998-12-18 2000-06-22 Joseph B. Santella, Iii N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
EP1140086A4 (en) 1998-12-18 2002-04-03 Du Pont Pharm Co N-UREIDOALKYL-PIPERIDINES FOR USE AS MODULATORS OF THE ACTIVITY OF CHIMIOKIN RECEPTORS
DE69926806D1 (de) * 1998-12-18 2005-09-22 Bristol Myers Squibb Pharma Co N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren
US6605623B1 (en) * 1998-12-18 2003-08-12 Bristol-Myers Squibb Pharma Co. N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
WO2000035454A1 (en) 1998-12-18 2000-06-22 Du Pont Pharmaceuticals Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
AU3386400A (en) * 1999-03-02 2000-09-21 Merck & Co., Inc. 3-alkyl substituted pyrrolidine modulators of chemokine receptor activity
CA2361366A1 (en) * 1999-03-26 2000-10-05 Nicholas Kindon Novel compounds
US6358979B1 (en) * 1999-06-11 2002-03-19 Merck & Co., Inc. N-cyclopentyl modulators of chemokine receptor activity
SE9902551D0 (sv) 1999-07-02 1999-07-02 Astra Pharma Prod Novel compounds
SE9902765D0 (sv) * 1999-07-21 1999-07-21 Astra Pharma Prod Novel compounds
CO5300399A1 (es) 2000-02-25 2003-07-31 Astrazeneca Ab Heterocicliocs que contienen nitrogeno, proceso para su preparacion y composiciones farmaceuticas que los contienen
AR033517A1 (es) 2000-04-08 2003-12-26 Astrazeneca Ab Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
CA2413421A1 (en) 2000-06-21 2001-12-27 Bristol-Myers Squibb Pharma Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
AU2001271357A1 (en) 2000-06-21 2002-01-02 Dupont Pharmaceuticals Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
AR034257A1 (es) * 2000-06-30 2004-02-18 Du Pont Pharm Co Compuesto ureido, composicion farmaceutica que lo comprende y metodo para modular la actividad del receptor de quimiocinas
GB0021670D0 (en) 2000-09-04 2000-10-18 Astrazeneca Ab Chemical compounds
US6855553B1 (en) 2000-10-02 2005-02-15 3M Innovative Properties Company Sample processing apparatus, methods and systems
WO2002030899A1 (en) 2000-10-09 2002-04-18 Novartis Ag N-(4-aryloxypiperidin-1-ylalkyl) cinnamic amides as ccr3 receptor antagonists
CA2436699A1 (en) 2000-12-21 2002-06-27 Warner-Lambert Company Llc Piperidine derivatives as subtype selective n-methyl-d-aspartate antagonists
SE517526C2 (sv) * 2001-01-12 2002-06-18 Volvo Lastvagnar Ab Tätningslist samt komponent innefattande en första och en andra del samt en tätningslist
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
GB0117899D0 (en) 2001-07-23 2001-09-12 Astrazeneca Ab Chemical compounds
TW200303304A (en) 2002-02-18 2003-09-01 Astrazeneca Ab Chemical compounds
WO2003082190A2 (en) 2002-03-26 2003-10-09 Merck & Co., Inc. Spirocyclic amides as cannabinoid receptor modulators
SE0400208D0 (sv) 2004-02-02 2004-02-02 Astrazeneca Ab Chemical compounds
TW200812582A (en) 2006-04-06 2008-03-16 Astrazeneca Ab Medicaments

Also Published As

Publication number Publication date
JP4435571B2 (ja) 2010-03-17
AU2003206554B2 (en) 2009-05-07
NO20043899L (no) 2004-11-17
CN100352807C (zh) 2007-12-05
AU2003206554A1 (en) 2003-09-04
EP1478624A1 (en) 2004-11-24
CN1633414A (zh) 2005-06-29
CA2472822A1 (en) 2003-08-21
NZ534296A (en) 2006-01-27
RU2007146928A (ru) 2009-06-27
DE60334074D1 (de) 2010-10-21
AR038566A1 (es) 2005-01-19
RU2004122114A (ru) 2005-05-27
CO5611135A2 (es) 2006-02-28
RU2330019C2 (ru) 2008-07-27
EP1478624B1 (en) 2010-09-08
JP2005525341A (ja) 2005-08-25
PL372538A1 (en) 2005-07-25
SG149695A1 (en) 2009-02-27
WO2003068743A1 (en) 2003-08-21
IL195011A0 (en) 2009-08-03
IS7381A (is) 2004-08-03
MXPA04007906A (es) 2004-10-15
US7709500B2 (en) 2010-05-04
KR20040084920A (ko) 2004-10-06
US20050107428A1 (en) 2005-05-19
TW200303304A (en) 2003-09-01
ATE480518T1 (de) 2010-09-15

Similar Documents

Publication Publication Date Title
BR0307477A (pt) Compostos quìmicos
BRPI0314325B8 (pt) derivados de aza-bicicloalquila, seu uso, seu processo de preparação e composição farmacêutica que os compreende
BR0210464A (pt) Composto, composição farmacêutica, processo para preparar um composto, e, uso de um composto
BR0206433A (pt) Composto, composição farmacêutica, processo para a prepapação de um composto, e, uso de um composto
NO20051826L (no) Heterosyklisk substituerte piperaziner for behandling av schizofreni
ATE381559T1 (de) Adamantan- und azabicyclooctan- und - nonanderivate, verfahren zu deren herstellung und deren verwendung als dpp-iv-inhibitoren
BR9910326A (pt) Processo para preeparar isoxazóis, composto, processo para preparar compostos, uso de compostos, e, processo para preparar tioéteres
BR9907886A (pt) Composto, uso do mesmo, composição farmacêutica, e, processo de tratamento ou profilaxia de doenças inflamatórias, por exemplo asma ou copd.
BR0312695A (pt) Derivados de 1h-pirrolidina-2,4-diona espirocìclicos substituìdos por cis-alcóxi
NO20092689L (no) Quinuclidinolderivater som muskarin reseptorantagonister
BR0316732A (pt) Derivados de 3-aminopirrolidina como moduladores de receptores de quimiocina
BR0317268A (pt) Compostos ativadores da pirazina e da piridina glucoquinase 5-substituìda, composição farmacêutica, uso e processo de preparação dos mesmos
BR0315143A (pt) Composto, processo para a preparação dos (r) e (s) - enanciÈmeros individuais ou misturas de enanciÈmeros e sais farmaceuticamente aceitáveis de um composto, composição farmacêutica, e, uso de um composto
AR041297A1 (es) Derivados de 4-pirrolidino- fenil- bencil eter
BR0109109A (pt) Composto, uso do mesmo, processo para prepará-lo, composição farmacêutica, e, método de tratar um estado doentio mediado por ccr5 em mamìferos
ATE424384T1 (de) Imidazolderivate, verfahren zu deren herstellung und deren anwendungen
BRPI0712889A8 (pt) composto, processo para a preparação de um composto, composto intermediário, e, composição farmacêutica.
BRPI0408160B1 (pt) Processo para o preparo de ésteres do ácido nicotínico substituído e intermediários de enamina para uso nesse processo
DE60213625D1 (de) Piperidinderivate und deren verwendung als modulatoren der chemokinaktivität (insbesondere der von ccr3)
BR0314966A (pt) Processo para preparar um composto, e, composto
BRPI0411308A (pt) composto, composição farmacêutica, processo para a preparação de um composto, e, uso de um composto
BR0205683A (pt) Processo para a preparação de derivados de piperazina, e, mesilato de um composto
DE60321452D1 (de) Als modulatoren der chemokinrezeptoraktivität geeignete piperidinderivate
BR0309668A (pt) Imidazolinilmetil aralquilsulfonamidas
ATE543803T1 (de) 3-ä2-(3-azylamino-2-oxo-2h-pyridin-1- yl)acetylaminoü-4-oxopentansäurederivate und deren verwendung als caspase-inhibitoren

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE A 9A ANUIDADE.